The US Justice Department sued a drug distribution company Thursday, accusing it of contributing to the opioid crisis by ignoring unusually high sales of certain substances in its pharmacies.
In the lawsuit AmerisourceBergen Corp. And two subsidiaries have been accused of failing to review the requests in sufficient detail.
The 87-page statement said entities affiliated with AmerisourceBergen “repeatedly refused or negligently failed” to report drug companies’ requests that “they had reason to know that they were being processed through illegal channels.” were allowing the diversion of opioids and other controlled substances into the
Colorado District Attorney Cole Finegan announced in a statement, “When pharmaceutical distributors like AmerisourceBergen fail in their duty to alert the DEA about suspicious orders of prescription drugs from pharmacies, they are exposing themselves to drug abuse capable of taking lives.” avoids an important liability in dealing with addictive substances.” trial.
Conshohocken, Pennsylvania-based AmerisourceBergen issued a statement in response alleging that the federal complaint improperly selected pharmacies among its tens of thousands of customers, “ignoring inaction” by the Department of Drug Enforcement.
“Even in those five instances selected by the Department of Justice, AmerisourceBergen verified that the pharmacy is DEA registered and licensed by the state board before fulfilling any orders, made customer inquiries, reported all sales of all controlled substances and reported suspicious controlled substance orders to the DEA at each of these pharmacies, for a total of hundreds of suspicious orders,” the company alleged.
Opioids have been linked to more than 500,000 deaths in the United States over the past two decades.
The Department of Justice denounces that the company has committed hundreds of thousands of violations of the national law on controlled substances over the past eight years, and demands that it be fined.
Among other things, the lawsuit describes how AmerisourceBergen sales representatives were assigned tasks related to identifying illegal diversion of opioids, a conflict of interest that led to illegality signals being unrecognized or ignored.